ArriVent BioPharma, Inc.
AVBP • NASDAQ
ArriVent BioPharma, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Zhengbin Yao, with a market cap of $947.2M.
CEOZhengbin Yao
Next Earnings
Upcoming earnings announcement for ArriVent BioPharma, Inc.
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.89
Earnings History
Past 8 earnings reports for ArriVent BioPharma, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$0.78Est: -$0.86 | +9.3% | - | — |  10-K |
| Nov 10, 2025 | Q3 2025 | -$0.83Est: -$0.78 | -6.4% | - | — | 10-Q |
| Aug 11, 2025 | Q2 2025 | -$0.90Est: -$0.71 | -26.8% | - | — | 10-Q |
| May 12, 2025 | Q1 2025 | -$1.90Est: -$0.69 | -175.4% | - | — | 10-Q |
| Mar 3, 2025 | Q4 2024 | -$0.61Est: -$1.10 | +44.5% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.61Est: -$0.82 | +25.6% | - | — | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.65Est: -$0.54 | -20.4% | - | — | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.70Est: -$1.05 | +33.3% | - | — | 10-Q |